Business
business
Tom Jones

Intel’s new CEO wants to build “The New Intel,” sending the stock back to where it was 10 days ago

Intel has appointed Lip-Bu Tan as its new CEO, as the industry veteran steps into what might well be “the toughest gig in US tech,” per Bloomberg. Still, investors are rallying around Tan, sending shares up almost 12% in premarket trading, taking INTC back toward the $23 mark it was trading at as recently as March 3.

Intel’s new chief replaces interim bosses standing in for Pat Gelsinger, whose December departure was cheered by investors after the chipmaker’s value slid ~$150 billion across his almost four-year tenure.

Tan previously sat on the board at Intel, though reportedly clashed with leadership at the time and left last August. In his first email to company employees yesterday, the new CEO wrote:

We have a chance to do something special together. In many ways, we are the founders of The New Intel. We will learn from past mistakes, use setbacks to strengthen our resolve and choose action over distraction to reach our full potential.

The appointment was announced on the same day as reports emerged about TSMC pitching Nvidia, Broadcom, and AMD on a joint venture to take over Intel Foundry, its loss-making division that makes chips for other companies. While Tan has yet to address the reported move, some have interpreted parts of his all-staff email as signals that he isn’t looking to break up the Intel business.

Intel’s new chief replaces interim bosses standing in for Pat Gelsinger, whose December departure was cheered by investors after the chipmaker’s value slid ~$150 billion across his almost four-year tenure.

Tan previously sat on the board at Intel, though reportedly clashed with leadership at the time and left last August. In his first email to company employees yesterday, the new CEO wrote:

We have a chance to do something special together. In many ways, we are the founders of The New Intel. We will learn from past mistakes, use setbacks to strengthen our resolve and choose action over distraction to reach our full potential.

The appointment was announced on the same day as reports emerged about TSMC pitching Nvidia, Broadcom, and AMD on a joint venture to take over Intel Foundry, its loss-making division that makes chips for other companies. While Tan has yet to address the reported move, some have interpreted parts of his all-staff email as signals that he isn’t looking to break up the Intel business.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.